GPT and Hepatitis: In the phase III trial, the incidence of grade 3 to 4 ALT increase was 12%, and 53% of patients experienced some degree of hypertransaminasemia.[7] The incidence of ALT elevation in pazopanib ranges from 46% to 60% in other study.[8] A subsequent meta-analysis of all pazopanib-containing trials confirmed a 42% incidence of all-grade ALT increase and an 8.2% incidence of high-grade ALT increase to above 5 times upper normal limit.[9] In preliminary trials of pazopanib in various solid tumors, there were rare reports of hepatitis with jaundice in <1% of patients.